eTheRNA develops immunotherapies that target the fundamental role of dendritic cells in the human immune system.
eTheRNA has raised €73M across 2 funding rounds from 7 investors, most recently a Series B round in Aug 2022. Based in Jette, Belgium; founded 2013; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-08-29 | Series B | €39M | FundPlus,Grand Pharma,LSP,Novalis LifeSciences,Omega Funds,PMV+1 more | View deal → |
| 2020-06-18 | Series B | €34M | — | View deal → |
